Linagliptin and Empagliflozin/Linagliptin Interaction

Drug interaction information between Linagliptin and Empagliflozin/Linagliptin.

Linagliptin and Empagliflozin/Linagliptin have a documented minor interaction in FDA labeling.

FDA drug labeling documents a minor-severity interaction between Linagliptin and Empagliflozin/Linagliptin. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.

Drug A

Linagliptin

DPP-4 Inhibitor

Drug B

Empagliflozin/Linagliptin

SGLT2 / DPP-4 Combination

How They Interact

Some drugs make your body process linagliptin too quickly, which can make the medication less effective at lowering your blood sugar.

FDA Label Information

Inducers of P-glycoprotein or CYP3A4 Enzymes Clinical Impact Rifampin decreased linagliptin exposure, suggesting that the efficacy of linagliptin may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. Intervention Use of alternative treatments is strongly recommended when linagliptin is to be administered with a strong P-gp or CYP3A4 inducer.

Linagliptin Also Interacts With

View all Linagliptin interactions →

Empagliflozin/Linagliptin Also Interacts With

View all Empagliflozin/Linagliptin interactions →

Frequently Asked Questions

What SPL severity band is on file for Linagliptin + Empagliflozin/Linagliptin?

Compiled FDA labeling labels this pair minor. That is a source-record field, not an individual medication-combination decision.

Which drug in this pair has the larger labeled-interaction portfolio?

Empagliflozin/Linagliptin has 11 labeled pairs on file vs Linagliptin's 9. In the minor band specifically: Linagliptin has 5 (also Topiramate, Rifampin, Phenytoin, Zonisamide); Empagliflozin/Linagliptin has 7 (also Empagliflozin, Topiramate, Lithium, Rifampin).

What mechanism field is on file for Linagliptin and Empagliflozin/Linagliptin?

Some drugs make your body process linagliptin too quickly, which can make the medication less effective at lowering your blood sugar.

Empagliflozin/Linagliptin's labeled portfolio outnumbers Linagliptin

SPL source-record counts only. This page's band is minor · classes on file: Linagliptin (DPP-4 Inhibitor); Empagliflozin/Linagliptin (SGLT2 / DPP-4 Combination).

Linagliptin

0 major · 4 moderate · 5 minor · 9 total

Empagliflozin/Linagliptin

0 major · 4 moderate · 7 minor · 11 total

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.